{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:38:11Z","timestamp":1793144291055,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fatigue is a common disabling symptom of multiple sclerosis (MS) and has a significantly negative impact on quality of life. Persons with MS enrolled in the North American Research Committee on Multiple Sclerosis (NARCOMS) Patient Registry are invited to complete follow-up surveys every six months to update their original registration information. One of these surveys was designed to focus on the severity and impact of fatigue, and its association with other clinical parameters of MS such as physical disability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In addition to the usual data collected in Registry update surveys such as demographic characteristics, MS-related medical history, disability and handicap, immunomodulatory and symptomatic therapies taken, and healthcare services used, the survey for this study included two validated self-report fatigue scales, the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) and questions about the use of symptomatic management for fatigue, both pharmacologic and non-pharmacologic treatments. This Registry update survey was mailed to all NARCOMS registrants (n = 18,595) in November 2002. Information provided by registry participants was approved for research purposes by the Yale University Institutional Review Board.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The response rate for the survey was 49.5% (9205\/18,595). Severe fatigue as measured with the FSS using the developer's recommended severity cutpoint of \u2265 36 was reported by 6691 (74%) of evaluable respondents (n = 9077). A higher prevalence of severe fatigue was observed in relapsing-worsening MS compared with relapsing-stable and primary progressive MS. A distinct pattern of fatigue was observed across the disability levels of the Patient-Determined Disease Steps (PDDS). Although there were no differences in the severity or impact of fatigue by immunomodulatory agents (IMA), respondents who recalled therapy changes in the prior six months reported different patterns of change in fatigue with lower fatigue levels reported after changing from interferon-\u03b2 to glatiramer acetate than after changing from glatiramer acetate to interferon-\u03b2. Concomitant therapy for fatigue was used by 47.2% of the 5799 survey respondents receiving IMA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Characterizing MS symptoms like fatigue can increase awareness about their impact on persons with MS and suggest recommendations for a care plan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7525-6-100","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T19:15:11Z","timestamp":1228504511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey"],"prefix":"10.1186","volume":"6","author":[{"given":"Olympia","family":"Hadjimichael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MerriKay","family":"Oleen-Burkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,14]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00023210-200317040-00002","volume":"17","author":"LB Krupp","year":"2003","unstructured":"Krupp LB: Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs 2003, 17: 225\u2013234. 10.2165\/00023210-200317040-00002","journal-title":"CNS Drugs"},{"key":"502_CR2","volume-title":"Multiple sclerosis clinical practice guideline","author":"Multiple Sclerosis Clinical Practice Guidelines Council","year":"1998","unstructured":"Multiple Sclerosis Clinical Practice Guidelines Council: Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. In Multiple sclerosis clinical practice guideline. Washington, DC: Paralyzed Veterans Association; 1998."},{"key":"502_CR3","first-page":"135","volume":"65","author":"JE Freal","year":"1984","unstructured":"Freal JE, Kraft GH, Coryell JK: Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984, 65: 135\u2013138.","journal-title":"Arch Phys Med Rehabil"},{"key":"502_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0317167100048691","volume":"21","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ: The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994, 21: 9\u201314.","journal-title":"Can J Neurol Sci"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/archneur.1988.00520280085020","volume":"45","author":"LB Krupp","year":"1988","unstructured":"Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC: Fatigue in multiple sclerosis. Arch Neurol 1988, 45: 435\u2013437.","journal-title":"Arch Neurol"},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1191\/135248506ms1262oa","volume":"12","author":"SL Minden","year":"2006","unstructured":"Minden SL, Frankel D, Hadden L, Perloffp J, Srinath KP, Hoaglin DC: The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006, 12: 24\u201338. 10.1191\/135248506ms1262oa","journal-title":"Mult Scler"},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1212\/WNL.46.3.632","volume":"46","author":"R Djaldetti","year":"1996","unstructured":"Djaldetti R, Ziv I, Achiron A, Melamed E: Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment. Neurology 1996, 46: 632\u2013635.","journal-title":"Neurology"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1600-0404.1995.tb00145.x","volume":"92","author":"C Colosimo","year":"1995","unstructured":"Colosimo C, Millefiorini E, Grasso MG, Vinci F, Fiorelli M, Koudriavtseva T, Pozzilli C: Fatigue in MS is associated with specific clinical features. Acta Neurol Scand 1995, 92: 353\u2013355.","journal-title":"Acta Neurol Scand"},{"key":"502_CR9","first-page":"247","volume":"12","author":"R Bergamaschi","year":"1997","unstructured":"Bergamaschi R, Romani A, Versino M, Poli R, Cosi V: Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997, 12: 247\u2013251.","journal-title":"Funct Neurol"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/archneur.1996.00550070080014","volume":"53","author":"JH Vercoulen","year":"1996","unstructured":"Vercoulen JH, Hommes OR, Swanink CM, Jongen PJ, Fennis JF, Galama JM, Meer JW, Bleijenberg G: The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol 1996, 53: 642\u2013649.","journal-title":"Arch Neurol"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/archneur.61.2.201","volume":"61","author":"MC Tartaglia","year":"2004","unstructured":"Tartaglia MC, Narayanan S, Francis SJ, Santos AC, De Stefano N, Lapierre Y, Arnold DL: The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004, 61: 201\u2013207. 10.1001\/archneur.61.2.201","journal-title":"Arch Neurol"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1545968306298934","volume":"22","author":"D Kos","year":"2008","unstructured":"Kos D, Kerckhofs E, Nagels G, D'Hooghe MB, Ilsbroukx S: Origin of Fatigue in Multiple Sclerosis: Review of the Literature. Neurorehabil Neural Repair 2008, 22: 91\u2013100.","journal-title":"Neurorehabil Neural Repair"},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s004150170222","volume":"248","author":"G Comi","year":"2001","unstructured":"Comi G, Leocani L, Rossi P, Colombo B: Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001, 248: 174\u2013179. 10.1007\/s004150170222","journal-title":"J Neurol"},{"key":"502_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1212\/WNL.53.5.1151","volume":"53","author":"R Bakshi","year":"1999","unstructured":"Bakshi R, Miletich RS, Henschel K, Shaikh ZA, Janardhan V, Wasay M, Stengel LM, Ekes R, Kinkel PR: Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999, 53: 1151\u20131153.","journal-title":"Neurology"},{"key":"502_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1191\/1352458503ms904oa","volume":"9","author":"R Bakshi","year":"2003","unstructured":"Bakshi R: Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003, 9: 219\u2013227. 10.1191\/1352458503ms904oa","journal-title":"Mult Scler"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0003-9993(96)90162-8","volume":"77","author":"CE Schwartz","year":"1996","unstructured":"Schwartz CE, Coulthard-Morris L, Zeng Q: Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996, 77: 165\u2013170. 10.1016\/S0003-9993(96)90162-8","journal-title":"Arch Phys Med Rehabil"},{"key":"502_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1212\/WNL.55.7.934","volume":"55","author":"LB Krupp","year":"2000","unstructured":"Krupp LB, Elkins LE: Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000, 55: 934\u2013939.","journal-title":"Neurology"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-510X(02)00312-X","volume":"205","author":"V Janardhan","year":"2002","unstructured":"Janardhan V, Bakshi R: Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002, 205: 51\u201358. 10.1016\/S0022-510X(02)00312-X","journal-title":"J Neurol Sci"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/135245850100700511","volume":"7","author":"MP Amato","year":"2001","unstructured":"Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L: Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001, 7: 340\u2013344.","journal-title":"Mult Scler"},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1212\/WNL.53.5.1098","volume":"53","author":"MW Nortvedt","year":"1999","unstructured":"Nortvedt MW, Riise T, Myhr KM, Nyland HI: Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999, 53: 1098\u20131103.","journal-title":"Neurology"},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/135245850000600213","volume":"6","author":"DC Kroencke","year":"2000","unstructured":"Kroencke DC, Lynch SG, Denney DR: Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler 2000, 6: 131\u2013136.","journal-title":"Mult Scler"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/135245850000600308","volume":"6","author":"R Bakshi","year":"2000","unstructured":"Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, Janardhan V, Dubey N, Kinkel PR: Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000, 6: 181\u2013185.","journal-title":"Mult Scler"},{"key":"502_CR23","first-page":"12","volume":"1","author":"T Vollmer","year":"1999","unstructured":"Vollmer T, Ni W, Hadjimichael O: The NARCOMS Patient Registry: A resource for investigators. Int J Mult Scler Care 1999, 1: 12.","journal-title":"Int J Mult Scler Care"},{"key":"502_CR24","first-page":"163","volume":"39","author":"TL Vollmer","year":"2002","unstructured":"Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J: Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans. J Rehabil Res Dev 2002, 39: 163\u2013174.","journal-title":"J Rehabil Res Dev"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1191\/1352458503ms953oa","volume":"9","author":"RA Marrie","year":"2003","unstructured":"Marrie RA, Hadjimichael O, Vollmer T: Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler 2003, 9: 461\u2013466. 10.1191\/1352458503ms953oa","journal-title":"Mult Scler"},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1191\/1352458505ms1167oa","volume":"11","author":"RA Marrie","year":"2005","unstructured":"Marrie RA, Cutter G, Tyry T, Hadjimichael O, Vollmer T: Validation of the NARCOMS Registry: pain assessment. Mult Scler 2005, 11: 338\u2013342. 10.1191\/1352458505ms1167oa","journal-title":"Mult Scler"},{"key":"502_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1191\/1352458505ms1216oa","volume":"11","author":"RA Marrie","year":"2005","unstructured":"Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T: Validation of the NARCOMS registry: fatigue assessment. Mult Scler 2005, 11: 583\u2013584. 10.1191\/1352458505ms1216oa","journal-title":"Mult Scler"},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/1352458506075031","volume":"13","author":"RA Marrie","year":"2007","unstructured":"Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T: Validation of the NARCOMS registry: diagnosis. Mult Scler 2007, 13: 770\u2013775. 10.1177\/1352458506075031","journal-title":"Mult Scler"},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46: 1121\u20131123.","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"502_CR30","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF: Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994, 18(Suppl 1):S79\u201383.","journal-title":"Clin Infect Dis"},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1176\/jnp.5.2.200","volume":"5","author":"CM Pepper","year":"1993","unstructured":"Pepper CM, Krupp LB, Friedberg F, Doscher C, Coyle PK: A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry Clin Neurosci 1993, 5: 200\u2013205.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1212\/WNL.52.1.63","volume":"52","author":"CE Schwartz","year":"1999","unstructured":"Schwartz CE, Vollmer T, Lee H: Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology 1999, 52: 63\u201370.","journal-title":"Neurology"},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1212\/WNL.45.2.251","volume":"45","author":"MJ Hohol","year":"1995","unstructured":"Hohol MJ, Orav EJ, Weiner HL: Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995, 45: 251\u2013255.","journal-title":"Neurology"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33: 1444\u20131452.","journal-title":"Neurology"},{"key":"502_CR35","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","volume":"45","author":"LB Krupp","year":"1995","unstructured":"Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45: 1956\u20131961.","journal-title":"Neurology"},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1191\/1352458502ms839oa","volume":"8","author":"P Flachenecker","year":"2002","unstructured":"Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV: Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002, 8: 523\u2013526. 10.1191\/1352458502ms839oa","journal-title":"Mult Scler"},{"key":"502_CR37","first-page":"127","volume":"4","author":"K Edgely","year":"1991","unstructured":"Edgely K, Sullivan MJL, Dehoux E: A survey of multiple sclerosis: Pt 2: determinations of employment status. Can J Rehab 1991, 4: 127\u2013132.","journal-title":"Can J Rehab"},{"key":"502_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1191\/1352458505ms1204oa","volume":"11","author":"MM Smith","year":"2005","unstructured":"Smith MM, Arnett PA: Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler 2005, 11: 602\u2013609. 10.1191\/1352458505ms1204oa","journal-title":"Mult Scler"},{"key":"502_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0003-9993(03)00614-2","volume":"85","author":"KL Johnson","year":"2004","unstructured":"Johnson KL, Yorkston KM, Klasner ER, Kuehn CM, Johnson E, Amtmann D: The cost and benefits of employment: a qualitative study of experiences of persons with multiple sclerosis. Arch Phys Med Rehabil 2004, 85: 201\u2013209. 10.1016\/S0003-9993(03)00614-2","journal-title":"Arch Phys Med Rehabil"},{"key":"502_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1191\/135245800678827572","volume":"6","author":"J Iriarte","year":"2000","unstructured":"Iriarte J, Subira ML, Castro P: Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000, 6: 124\u2013130. 10.1191\/135245800678827572","journal-title":"Mult Scler"},{"key":"502_CR41","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/jnnp.2002.007724","volume":"75","author":"LM Metz","year":"2004","unstructured":"Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, Bell RB, Yeung M, Murphy WF, Stoian CA, et al.: The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004, 75: 1045\u20131047. 10.1136\/jnnp.2002.007724","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"502_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/jnnp.2005.065805","volume":"77","author":"C Heesen","year":"2006","unstructured":"Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM: Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006, 77: 34\u201339. 10.1136\/jnnp.2005.065805","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"502_CR43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1212\/WNL.56.6.702","volume":"56","author":"O Neuhaus","year":"2001","unstructured":"Neuhaus O, Farina C, Wekerle H, Hohlfeld R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001, 56: 702\u2013708.","journal-title":"Neurology"},{"key":"502_CR44","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.58.8_suppl_4.S3","volume":"58","author":"S Dhib-Jalbut","year":"2002","unstructured":"Dhib-Jalbut S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002, 58: S3\u20139. 10.1159\/000065979","journal-title":"Neurology"},{"key":"502_CR45","doi-asserted-by":"publisher","first-page":"10821","DOI":"10.1073\/pnas.94.20.10821","volume":"94","author":"R Aharoni","year":"1997","unstructured":"Aharoni R, Teitelbaum D, Sela M, Arnon R: Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997, 94: 10821\u201310826. 10.1073\/pnas.94.20.10821","journal-title":"Proc Natl Acad Sci USA"},{"key":"502_CR46","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/1352458506074510","volume":"13","author":"RM Valenzuela","year":"2007","unstructured":"Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S: Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007, 13: 754\u2013762. 10.1177\/1352458506074510","journal-title":"Mult Scler"},{"key":"502_CR47","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","volume":"53","author":"EU Walther","year":"1999","unstructured":"Walther EU, Hohlfeld R: Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999, 53: 1622\u20131627.","journal-title":"Neurology"},{"key":"502_CR48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.46.2.552","volume":"46","author":"LK Neilley","year":"1996","unstructured":"Neilley LK, Goodin DS, Goodkin DE, Hauser SL: Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996, 46: 552\u2013554.","journal-title":"Neurology"},{"key":"502_CR49","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.apmr.2004.11.048","volume":"86","author":"M Hatzakis Jr","year":"2005","unstructured":"Hatzakis M Jr, Turner AP, Williams RM, Bowen JD, Rodriquez AA, Haselkorn JK: Predictors of prescriptions for management of fatigue among veterans with multiple sclerosis. Arch Phys Med Rehabil 2005, 86: 1376\u20131380. 10.1016\/j.apmr.2004.11.048","journal-title":"Arch Phys Med Rehabil"},{"key":"502_CR50","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1191\/1352458503ms957oa","volume":"9","author":"G Brichetto","year":"2003","unstructured":"Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C: Symptomatic medication use in multiple sclerosis. Mult Scler 2003, 9: 458\u2013460. 10.1191\/1352458503ms957oa","journal-title":"Mult Scler"},{"key":"502_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/archneur.1994.00540150090022","volume":"51","author":"CH Polman","year":"1994","unstructured":"Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC: 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994, 51: 292\u2013296.","journal-title":"Arch Neurol"},{"key":"502_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1207\/s15324826an0503_5","volume":"5","author":"RH Paul","year":"1998","unstructured":"Paul RH, Beatty WW, Schneider R, Blanco CR, Hames KA: Cognitive and physical fatigue in multiple sclerosis: relations between self-report and objective performance. Appl Neuropsychol 1998, 5: 143\u2013148. 10.1207\/s15324826an0503_5","journal-title":"Appl Neuropsychol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-6-100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:15:17Z","timestamp":1630487717000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-6-100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,14]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-6-100","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,14]]},"assertion":[{"value":"30 April 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"100"}}